The primary role of this medication is to help with symptoms related to inflammatory or irritative states that interfere with daily functioning. Diclofenac extended-release formulations are generally used across conditions presenting with chronic, disruptive symptoms.

---

Symptomatic Support and Therapeutic Domains

This formulation is generally used across conditions characterized by persistent inflammation and degenerative joint changes. The types of conditions for which this medication is considered relevant include Rheumatoid Arthritis, Osteoarthritis, Ankylosing Spondylitis, and acute localized issues such as a gout attack, tendinitis, or sprains. It is also applied in settings where short-term symptomatic assistance is needed, such as managing post-operative pain and the intense cyclical discomfort associated with Primary Dysmenorrhoea.

“A key benefit of this prolonged-release form is that it may help provide supportive relief during periods of chronic joint pain, assisting with maintaining functional stability.”

By easing symptoms that may become severe, such as pain, swelling, and tenderness that cluster around these conditions, the medication helps ease the overall symptom burden. It is applied in clinical settings marked by ongoing patient discomfort to assist with maintaining functional stability.

---

Quick Fact Block

Quick Fact: Relief for Pain & Inflammation
Main Symptom Focus: Chronic joint pain, inflammatory swelling, and acute musculoskeletal tenderness.
Key Use Scenario: Situations requiring sustained pain control over an extended period, such as managing morning stiffness in rheumatic disease.

Regulatory References

1. NIH MedlinePlus Drug Information

Who Can and Cannot Use Diclofenac Retard?

This section describes the official population eligibility and non-eligibility rules for Diclofenac Retard, based strictly on government regulatory documents.

Eligibility Status	Patient Population Constraints
Allowed	Adults are the standard eligible population under labeled conditions.
Contraindicated (Must Not Use)	Individuals with known hypersensitivity to Diclofenac or other NSAIDs (including aspirin-induced asthma). Patients with active GI ulceration, bleeding, or perforation, or history related to prior NSAID therapy. Individuals with severe hepatic or renal impairment. Patients with established congestive heart failure (NYHA Class II-IV) or other severe established cardiovascular disease (per EU/UK labeling). Women in the last trimester of pregnancy.
Restricted Use (Caution)	Elderly patients require particular caution and the lowest effective dose. Use is generally not recommended for children and adolescents (under 18 years). Mild to moderate hepatic or renal impairment requires careful monitoring. Females attempting conception should be aware that use may impair fertility.

Official regulatory documents establish who can and cannot use the medicine by defining specific population exclusions based on systemic health status and prior hypersensitivity. Eligibility is constrained by pre-existing conditions like severe organ impairment or established severe cardiovascular disease, which are formal contraindications. Conditional use is defined for populations like the elderly or those with mild organ dysfunction, demonstrating that eligibility requires careful regulatory consideration.

Diclofenac Retard Interactions with other medicines and products

This section summarizes interactions documented in official government regulatory information for Diclofenac Retard (diclofenac sodium prolonged-release). This information is descriptive and does not constitute medical advice.

Formally Documented Interaction Constraints

Category	Documented Constraint
Prohibited Combinations	The co-administration of Diclofenac Retard with other systemic NSAIDs (including COX-2 inhibitors) and Aspirin is generally avoided or contraindicated due to significantly increased risk of serious gastrointestinal events.
Procedural Restriction	Use is contraindicated for managing peri-operative pain in the setting of Coronary Artery Bypass Graft (CABG) surgery.
Substance Warning	Co-use with Alcohol carries a possibly increased risk of gastrointestinal bleeding and ulceration.

Interactions Affecting Concentration and Risk

Interactions may cause changes in drug concentration or increase the risk of specific adverse effects, as noted in prescribing information:

• Lithium, Digoxin, and Methotrexate: Diclofenac has been reported to increase the plasma concentrations of these medicines by impairing their excretion, necessitating concentration monitoring.
• CYP2C9 Modulators: Medicines that inhibit or induce the CYP2C9 enzyme may significantly alter the overall exposure of diclofenac in the body.
• Bleeding Risk: Concurrent use with Anticoagulants (e.g., Warfarin), Corticosteroids, and Anti-platelet agents (e.g., SSRIs) elevates the risk of bleeding, requiring close monitoring.
• Hyperkalaemia Risk: Co-administration with ACE Inhibitors, Potassium-sparing Diuretics, or Cyclosporine may lead to an increased risk of elevated serum potassium levels.
• Antihypertensive Effects: Diclofenac may reduce the intended antihypertensive effects of Diuretics, ACE Inhibitors, and other antihypertensives.

1. Primary Action: Inhibition of Eicosanoid Synthesis

The primary action of diclofenac involves the competitive inhibition of the Cyclooxygenase (COX) enzymes, specifically COX-2, which are central to the Arachidonic Acid Cascade. By blocking these enzymes, the molecule suppresses the generation of lipid mediators, such as Prostaglandin E2 (PGE2). This reduction is critical because these prostanoids are key mediators of local vascular permeability changes and peripheral nociceptor sensitization.

2. Modulation of Nociceptive Signaling

The mechanism extends beyond prostanoid reduction to influence specific nociceptive pathways. Diclofenac is documented to modulate the release of neuropeptides, such as Substance P, from nerve fibers and to affect the activity of Acid-Sensing Ion Channels (ASICs) in the periphery. This peripheral action is relevant for systems requiring targeted pathway adjustment, contributing to the modulation of nociceptive input to the central nervous system.

3. Central Thermoregulatory Adjustment

A separate component of the mechanism involves action within the central nervous system, specifically the hypothalamus. Here, the drug's COX-inhibitory action blocks the synthesis of pyrogen-induced PGE2, which influences the body's core temperature setpoint. This mechanism engages pathways that influence central temperature control and modulate the systemic effects of the febrile response.

Official Administration Guidelines for Diclofenac Retard

Diclofenac Retard is a prolonged-release oral formulation and is used according to established guidelines to ensure proper release of the active ingredient and minimize risks.

Administration Details

Feature	Official Rule
Route of Administration	Oral use
Standard Adult Dose	One 100 mg prolonged-release tablet or capsule daily.
Maximum Daily Dose	Should not exceed 150 mg (using supplementation with conventional forms if necessary).
Timing in Relation to Meals	Take the dose whole with liquid, preferably with or after food.
Preparation Requirements	Swallow the tablet or capsule whole. Do not crush, chew, or break it, as this would compromise the special slow-release system.

Dosing Principles

General guidance indicates that the lowest effective dose should be used for the shortest duration necessary to control symptoms. This principle is especially important given the association between dose, duration, and cardiovascular risk.

Age-Specific Use

• Children and Adolescents: Diclofenac Retard 100 mg prolonged-release tablets are not recommended for children and adolescents.
• Elderly Patients: Although no specific dose adjustment is mandated, particular caution is advised. The lowest effective dosage compatible with adequate clinical control should be employed in frail elderly patients or those with a low body weight.

Missed Dose Instructions

If a dose is missed, take it as soon as you remember, unless it is almost time for your next scheduled dose. In this case, skip the missed dose and take the next dose at the usual time. Do not take a double dose to make up for a forgotten dose.

Research Evidence / Overview of Studies for Diclofenac Retard

The research for Diclofenac prolonged-release was studied for several conditions marked by functional limitations and outcomes related to physical discomfort. This overview summarizes the structure of the clinical evaluation and areas where the evidence remains limited or uncertain.

---

Evidence for Use in Chronic Joint Conditions (Osteoarthritis and Rheumatoid Arthritis)

This section will describe the types of clinical studies, including large Randomized Controlled Trials (RCTs) and Systematic Reviews, that have explored Diclofenac prolonged-release for persistent symptoms related to Osteoarthritis and Rheumatoid Arthritis. The focus will be on study designs that examined patient function and subjective measures of joint discomfort.

Research for Osteoarthritis (OA) and Rheumatoid Arthritis (RA) was evaluated in adult and older adult populations, focusing on outcomes related to physical discomfort and functional status. Studies report how symptoms evolved in the observed populations over short- to intermediate-term follow-up (up to six months). For RA, research focused on symptom management as an adjunct treatment, and was not studied for structural joint damage outcomes. Many comparative trials utilized the immediate-release form of diclofenac, limiting direct assessment of the prolonged-release formulation.

---

Research Base for Spondyloarthropathies (Ankylosing Spondylitis)

This part will describe the types of clinical studies, including RCTs, that have evaluated the medication for Ankylosing Spondylitis. It will detail the functional and symptomatic outcomes measured, as well as the research that has attempted to track structural changes in the spine.

Studies explored Ankylosing Spondylitis (AS), examining functional capacity and pain. Longer-term research was observed in evaluation of spinal structure. However, studies exploring the effect on disease progression yielded mixed findings, which means evidence quality varies across studies for this particular condition.

---

Research for Acute and Cyclical Pain Management

This heading will outline the evidence structure from RCTs and Systematic Reviews for short-term and intermittent uses, such as managing Primary Dysmenorrhoea and Acute Post-Operative Pain. It will distinguish the study types used for these short-duration conditions.

The medicine was studied for conditions characterized by fluctuating or episodic manifestations over very short follow-up durations. In many cases, comparative evidence is lacking because studies was observed in comparison to the immediate-release form for these highly acute scenarios.

---

Long-Term Studies and Follow-Up Duration

This section will detail the maximum durations for which patient outcomes have been tracked in published clinical trials and regulatory summaries. It will summarize the available data on continuous use and its tracking over intermediate-term (e.g., six-month) periods.

Observation in core clinical research typically extends to the intermediate-term. While some research has been studied for periods up to two years, long-term outcomes are not fully established, and there is limited information related to the sustained performance of the prolonged-release formulation.

---

Evidence in Specific Populations

This part will summarize what the research base reports regarding the study of the medication in specific patient cohorts, such as older adults with chronic conditions and the available data for use in pediatric groups.

Studies monitored outcomes in cohorts that included older adults. However, research in pediatric populations is limited, and the evidence quality varies across studies, with certainty remaining low for these younger age groups.

---

What Remains Uncertain in the Evidence Landscape

This final section will synthesize and describe the major research gaps, key limitations reported across trials, and areas where evidence is considered less certain or conflicting, such as the data surrounding long-term disease progression or the use of the prolonged-release form in highly acute settings.

The primary limitation is that follow-up durations were limited for many chronic disease outcomes. The results apply only to the populations studied, and comparative evidence for the prolonged-release form is often lacking. Research provides context but not individual predictions, and the evidence highlights what is known—and what is still uncertain.

Key Studies & References

1. WHO Model List of Essential Medicines (Diclofenac Listing)
2. NIH DailyMed and MedlinePlus Drug Information (Diclofenac Extended-Release Monograph)

Common questions about Diclofenac Retard (FAQ)

Q: How long does Diclofenac Retard take to start working for pain?

A: Official product information on the prolonged-release formulation indicates that the active ingredient reaches its peak concentration in the bloodstream after approximately 2.5 hours. This peak concentration represents the time when the drug's availability for effect is highest, as described in regulatory documents.

Q: Can Diclofenac Retard cause stomach issues?

A: Regulatory documents indicate that adverse effects involving the stomach and intestines are frequently reported. Common symptoms can include gastrointestinal disturbances such as abdominal pain, nausea, and indigestion (dyspepsia).

Q: Is heartburn a common side effect of Diclofenac Retard?

A: Heartburn is listed as a potential symptom of the gastrointestinal disturbances associated with this medicine. Official safety information classifies these digestive issues as common adverse events.

Q: Does Diclofenac Retard affect blood pressure?

A: Regulatory documents note that fluid retention and oedema (swelling) have been reported with the use of this medicine. Due to this potential effect, particular caution is noted in official documentation for individuals who have or have previously had high blood pressure.

Q: Can taking Diclofenac Retard for a long time cause problems?

A: Official warnings describe that the risk of serious adverse events, including issues affecting the heart and digestive system, is dose- and duration-dependent. This means that the risk may be higher with high doses and with prolonged treatment over time.

Q: Can I take Diclofenac Retard if I'm already taking blood thinners?

A: Official guidance states that caution is specifically noted if this medicine is used alongside blood thinners (anticoagulants, such as warfarin) or other antiplatelet agents. This combination is noted to increase the risk of bleeding and is an area where close medical monitoring is indicated.

Q: Is it safe to drink alcohol while using Diclofenac Retard?

A: Regulatory documents include a warning that concurrent use with alcohol is associated with a possibly increased risk of gastrointestinal bleeding and ulceration.

Q: Is Diclofenac Retard suitable for people with kidney problems?

A: Use is contraindicated for individuals with severe kidney impairment. For patients with mild to moderate kidney problems, the medicine requires careful medical monitoring and caution is advised.

Q: Does Diclofenac Retard affect fertility in men or women?

A: Official prescribing information states that for women who are actively attempting to become pregnant, the use of this medicine may impair fertility. There is no specific statement regarding male fertility in these documents.

Q: Can I take Diclofenac Retard with antacids for stomach protection?

A: While specific interactions with over-the-counter antacids are not uniformly listed, regulatory information does mention that a healthcare professional may prescribe another medicine to protect the stomach for certain patients who are at risk of gastrointestinal adverse events.

Q: Is it okay to take Diclofenac Retard on an empty stomach?

A: Official guidance states that the medicine should be taken preferably with or after food. Given the regulatory warnings regarding serious gastrointestinal risks, taking the medicine without food is generally discouraged.

Q: Do you get sleepy or dizzy after taking Diclofenac Retard?

A: Some people have occasionally reported feeling dizzy, tired, or sleepy while taking this medicine. Regulatory information also notes that problems with eyesight have been reported in rare cases.

Q: What foods should I avoid when taking Diclofenac Retard?

A: Regulatory documents do not specifically list particular foods to be avoided while using this medicine. The only substance warning documented in relation to increased risk is the concurrent use of alcohol.

Q: Is Diclofenac Retard generally safe for older adults?

A: Caution is noted for older adults, as they generally face an increased risk of serious adverse reactions, particularly gastrointestinal bleeding and perforation. Regulatory guidance recommends using the lowest effective dose for this population.

Q: Is Diclofenac Retard prescribed for headaches or migraines?

A: According to the official indications (labeled uses), this prolonged-release formulation is not listed for the treatment of typical headaches or migraines.

Q: Does Diclofenac Retard treat inflammation or just mask the pain?

A: Regulatory classification defines this medicine as a non-steroidal agent with both analgesic (pain relieving) and anti-inflammatory properties. It is documented to function by inhibiting the synthesis of prostaglandins, which are key chemical messengers for inflammation.

Q: Does Diclofenac Retard accumulate in the body over time?

A: Based on pharmacokinetic data included in regulatory information, no accumulation of the active ingredient occurs in the body, provided that the recommended dosage intervals are observed.

Q: Is it safe to drive or operate machinery after taking Diclofenac Retard?

A: Caution is noted in regulatory documents. Patients who experience dizziness, sleepiness (somnolence), or other central nervous system effects are instructed to refrain from driving or operating machinery until these symptoms have cleared.

Q: Can Diclofenac Retard cause swelling in the hands or feet?

A: Regulatory documents note that fluid retention and oedema (a medical term for swelling, commonly seen in the hands or feet) have been reported in relation to the use of this class of medicine.

Q: Do other medications affect how long Diclofenac Retard stays in the system?

A: Yes. Official information notes that medicines which affect the CYP2C9 enzyme may alter the overall exposure of diclofenac in the body. This includes altering how quickly the medicine is metabolized and eliminated, thus influencing its duration in the system.

Q: Can Diclofenac Retard be used for pain after surgery?

A: The medicine is indicated for managing acute pain, and studies have examined its use in acute post-operative pain. However, it is strictly contraindicated for peri-operative pain management in the setting of Coronary Artery Bypass Graft (CABG) surgery.

Q: Is there a maximum length of time Diclofenac Retard can be used?

A: Regulatory guidance emphasizes the principle that the medicine should be used for the shortest duration necessary to control symptoms. This guidance exists because the risk of serious adverse events is described as being related to the duration of treatment.

Q: Is the 'retard' formulation designed to reduce side effects?

A: Yes. One stated goal of the prolonged-release (retard) formulation design is to maintain a relatively constant rate of absorption. This design characteristic helps to reduce the occurrence of certain side effects compared to immediate-release forms.

Q: Does Diclofenac Retard contain lactose or gluten?

A: Official documents list the ingredients (excipients) for specific prolonged-release formulations. Some of these formulations contain lactose and/or sucrose (sugars). Regulatory documents do not uniformly list or forbid gluten.

Q: Are allergic reactions to Diclofenac Retard common?

A: Severe allergic reactions, including anaphylactic reactions, are described in regulatory documents as rare events that can occur with use, even without prior exposure to the medicine.

Q: Does Diclofenac Retard have sedative properties?

A: Regulatory documents note that some people have occasionally reported feeling sleepy while taking this medicine, which is a mild sedative-like effect.

Storage and Disposal Requirements

Official labeling for Diclofenac Prolonged-Release Tablets dictates specific handling and storage constraints to preserve product quality and safety.

Requirement	Official Statement
Storage Temperature	Store at controlled room temperature, typically 20 °C to 25 °C.
Container & Protection	Keep in the original container and in a tight container; Do not freeze.
Child Safety	Must be kept out of the sight and reach of children.
Disposal Instructions	Unused or expired tablets should be disposed of via a drug take-back program.

If a take-back program is unavailable, discard the tablets with household trash by mixing them with an unappealing substance, and do not flush the product.